Drugs / TEZAMPANEL ANHYDROUS
TEZAMPANEL ANHYDROUS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06538558 | Oct 2024 → Oct 2025 overdue | substance-related disorder | Proniras Corporation | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00567086 | Oct 2006 → Aug 2007 | migraine disorder | TorreyPines Therapeutics | Completed | No outcome recorded |
Press releases naming this drug 2 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEZAMPANEL ANHYDROUS | ChEMBL registry synonym — accepted as the source's own label CHEMBL14935 ↗ |
| Known as | LY-293,558 | ChEMBL registry synonym — accepted as the source's own label CHEMBL14935 ↗ |
| Known as | NGX-424 | ChEMBL registry synonym — accepted as the source's own label CHEMBL14935 ↗ |
| Known as | TEZAMPANEL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00567086 ↗ |
| Known as | Tezampanel hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL14935 ↗ |
| Known as | TZP | “This study is examining the use of Tezampanel (TZP) for treatment of Opioid Withdrawal Syndrome (OWS) in participants with Opioid Use Disorder (OUD).” NCT06538558 ↗ |
| Modality | Small molecule | — CHEMBL14935 ↗ |
| Route | Subcutaneous | “single sc administration of TEZAMPANEL” NCT00567086 ↗ |